德展健康(000813) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥135,160,087.88, a decrease of 29.90% compared to ¥192,816,625.91 in the same period last year[5] - Net profit attributable to shareholders was ¥1,859,373.76, down 93.89% from ¥30,445,095.31 year-on-year[5] - The net cash flow from operating activities was ¥49,861,633.81, a decline of 61.77% compared to ¥130,435,562.96 in the previous year[5] - Basic and diluted earnings per share were both ¥0.0008, representing a decrease of 94.12% from ¥0.0136 in the same period last year[5] - Total operating revenue for Q1 2023 was ¥135,160,087.88, a decrease of 29.9% compared to ¥192,816,625.91 in the same period last year[22] - Net profit for Q1 2023 was ¥582,608.11, a significant decline from ¥22,929,114.75 in Q1 2022, representing a decrease of 97.5%[24] - Total comprehensive income for the period amounted to CNY 582,608.11, a decrease from CNY 22,929,114.75 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,554,524,795.94, down 2.11% from ¥5,674,395,997.63 at the end of the previous year[5] - Total assets decreased to ¥5,554,524,795.94 from ¥5,674,395,997.63, a reduction of 2.1%[21] - Total liabilities decreased to ¥328,445,794.71 from ¥390,381,648.39, a decline of 15.9%[21] Cash Flow - The company's cash and cash equivalents increased to ¥2,985,284,796.13 from ¥2,599,135,458.30 at the beginning of the year, reflecting a growth of 14.8%[20] - Cash inflow from investment activities reached CNY 400,005,200.00, significantly higher than CNY 80,551,396.03 in the previous period, indicating a growth of 396.5%[27] - Net cash flow from investment activities was CNY 386,383,653.20, compared to a negative CNY 15,445,078.29 in the previous period, showing a substantial turnaround[27] - Total cash inflow from operating activities was CNY 187,407,681.48, down from CNY 299,649,594.13 in the previous period, a decline of about 37.4%[26] - Total cash outflow from operating activities was CNY 137,546,047.67, compared to CNY 169,214,031.17 in the previous period, a decrease of approximately 18.7%[26] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 50,330[12] - Major shareholders include Meilin Holdings Group with 19.11% and Shanghai Yueye Equity Investment Management with 18.60%[13] - The company’s major shareholder, Meilin Holdings, holds 425,470,400 shares, representing 19.11% of the total share capital[17] - The company’s top ten shareholders include significant stakes from Xinjiang Kaidi Investment and Xinjiang Kaidi Mining, with holdings of 409,748,445 shares and 104,039,367 shares respectively[14] - The company’s top ten shareholders have a combined holding of 1.17% in the repurchase special account[15] Share Repurchase - As of March 31, 2023, the company repurchased a total of 26,105,140 shares, accounting for 1.17% of the total share capital, with a total payment of RMB 91,674,284 (excluding transaction fees)[15] - The company has repurchased a total of 25,323,440 shares, with the highest transaction price at RMB 3.88 per share and the lowest at RMB 2.94 per share, totaling RMB 88,756,868 (excluding transaction fees)[17] - The company’s total share repurchase reached 24,823,440 shares, approximately 1.11% of the total share capital, with a total payment of RMB 86,881,868 (excluding transaction fees)[16] - The company’s stock repurchase plan allows for a maximum reduction of 22,263,945 shares, not exceeding 1% of the total share capital[17] Investment and Projects - The company plans to invest approximately RMB 489.36 million in the Hainan Dezheng International Medical and Health Complex project, with a total construction area of about 71,828 square meters and a construction period of 33 months[17] - The company’s subsidiary, Jialin Pharmaceutical, participated in the eighth national centralized procurement and is expected to win the bid for Amlodipine Atorvastatin Calcium Tablets[17] Research and Development - Research and development expenses for Q1 2023 were ¥11,907,421.27, an increase of 11.1% compared to ¥10,715,438.38 in Q1 2022[22] Financial Expenses - The company reported a financial expense of -¥19,002,480.13, compared to -¥13,068,207.92 in the previous year, indicating an increase in financial costs[24] Audit Status - The first quarter report was not audited[28]